Enoxaparin Restenosis (ERA) Trial. - ERA

Description:

ERA was a randomized, placebo-controlled, double-blind trial designed to evaluate whether enoxaparin given subcutaneously daily for 28 days after successful angioplasty would be associated with a reduction in restenosis.